CTC1 and STN1 presented consistently lower expression in tumor samples for the majority of cancers, including bladder urothelial carcinoma (BLCA), BRCA, COAD, kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC) (p < 0.05). This evidence concerns the gene CTC1 and bladder transitional cell carcinoma.